Author ORCID Identifier
Collections of lymphocytes to be genetically modified to treat hematologic malignancies have seen a dramatic increase over the last few years as commercial products have been approved. Reports of new products in development that can possibly treat solid organ malignancies represent a massive change in the field. Apheresis is at the center of the collection of cells for the manufacture of these chimeric-antigen receptor therapy products. The expansion of these collections represents one of the areas of apheresis procedures growth. This review will summarize concepts important to this type of collection and variables that need to be optimized to obtain desired cell yields while increasing patients' safety.
adverse events, apheresis, CAR T, cell collections, chimeric-antigen receptor therapy, efficiency, variables
European Journal of Haematology
© 2023 The Author
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Maitta RW. Apheresis collection of mononuclear cells for chimeric-antigen receptor therapies. Eur J Haematol. 2023;1‐5. doi:10.1111/ejh.14071